New formulation: Calcitriol (Vectical), a Vitamin D analogue, was approved on January 23, 2009, for the treatment of mild-to-moderate plaque psoriasis
Calcitriol is a vitamin D analogue that was approved on January 23, 2009, for the topical treatment of mild-to-moderate plaque psoriasis in adults aged ≥18 years. The mechanism of action by which calcitriol exerts its effects on plaque psoriasis has not yet been established.
Efficacy. The efficacy of this agent was assessed in 2 multicenter, double-blind studies. A total of 839 patients were randomized to treatment with either calcitriol ointment 3 mcg/g or vehicle ointment twice daily for 8 weeks. The primary end point was the percentage of patients classified as having "clear" or "minimal" disease with a ≥2-grade change from baseline at 8 weeks. In Study 1, 23.4% of calcitriol-treated patients and 14.4% of vehicle-treated patients achieved this end point; in Study 2, 20.5% of calcitriol-treated patients and 6.6% of vehicle-treated patients achieved this end point.
Safety. In clinical trials, hypercalcemia was observed more frequently in calcitriol-treated patients than in vehicle-treated patients. Patients should avoid excessive exposure of treatment areas to natural or artificial sunlight. The most common adverse events associated with calcitriol treatment include laboratory test abnormalities, urine abnormalities, psoriasis, hypercalciuria, and pruritus.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More